Boston Scientific (BSX) Tops Q4 EPS by 1c

Boston Scientific (NYSE: BSX) reported Q4 EPS of $0.45, $0.01 better than the analyst estimate of $0.44. Revenue for the quarter came in at $3.13 billion versus the consensus estimate of $3.11 billion.

GUIDANCE:

Boston Scientific sees Q1 2022 EPS of $0.38-$0.40, versus the consensus of $0.41.

Boston Scientific sees FY2022 EPS of $1.73-$1.79, versus the consensus of $1.87.

For earnings history and earnings-related data on Boston Scientific (BSX) click here.

You May Also Be Interested In

• LeonaBio (LONA) Price Target Cut to $17 by Citizens Amid Pipeline Development
• Vislink Technologies Inc. (VISL) Misses Q2 EPS by 7c
• Brainstorm Cell Therapeutics (BCLI) Misses Q2 EPS by 6c